PSNL [NASD]
Personalis, Inc.
Index- P/E- EPS (ttm)-1.81 Insider Own2.10% Shs Outstand45.00M Perf Week8.24%
Market Cap163.50M Forward P/E- EPS next Y-2.64 Insider Trans22.59% Shs Float44.73M Perf Month-10.46%
Income-81.00M PEG- EPS next Q-0.63 Inst Own89.80% Short Float5.22% Perf Quarter-53.30%
Sales79.80M P/S2.05 EPS this Y-23.80% Inst Trans2.24% Short Ratio3.72 Perf Half Y-72.96%
Book/sh6.37 P/B0.58 EPS next Y-5.60% ROA-20.70% Target Price19.00 Perf Year-86.74%
Cash/sh6.00 P/C0.61 EPS next 5Y- ROE-25.70% 52W Range3.13 - 28.47 Perf YTD-74.21%
Dividend- P/FCF- EPS past 5Y- ROI-20.80% 52W High-87.07% Beta-
Dividend %- Quick Ratio7.20 Sales past 5Y- Gross Margin35.70% 52W Low17.57% ATR0.39
Employees325 Current Ratio7.40 Sales Q/Q-27.30% Oper. Margin- RSI (14)43.70 Volatility10.78% 11.20%
OptionableYes Debt/Eq0.01 EPS Q/Q-113.60% Profit Margin- Rel Volume0.85 Prev Close3.91
ShortableYes LT Debt/Eq0.01 EarningsMay 04 AMC Payout- Avg Volume627.34K Price3.68
Recom1.70 SMA20-2.61% SMA50-21.18% SMA200-68.32% Volume534,816 Change-5.88%
Jan-07-22Upgrade BofA Securities Neutral → Buy $27 → $23
Nov-05-21Downgrade Morgan Stanley Overweight → Equal-Weight
Nov-03-21Downgrade Needham Buy → Hold
Oct-15-21Resumed Cowen Outperform
Sep-20-21Reiterated Needham Buy $33 → $28
May-06-21Upgrade Oppenheimer Perform → Outperform $28
Jan-28-21Initiated Truist Buy $50
Jan-04-21Downgrade BofA Securities Buy → Neutral $40
Nov-12-20Reiterated Needham Buy $25 → $32
Nov-06-20Downgrade Oppenheimer Outperform → Perform
Oct-19-20Initiated Citigroup Buy $35
Oct-08-20Initiated BTIG Research Buy $35
Aug-27-20Initiated H.C. Wainwright Buy $30
Aug-18-20Initiated Needham Buy $25
Sep-26-19Upgrade BofA/Merrill Neutral → Buy $22
Jul-15-19Initiated Oppenheimer Outperform $29
Jul-15-19Initiated Morgan Stanley Overweight $28
Jul-15-19Initiated Cowen Outperform
Jul-15-19Initiated BofA/Merrill Neutral $27
Jun-09-22 06:54AM  
May-04-22 06:05PM  
04:01PM  
01:44PM  
Apr-28-22 04:01PM  
Apr-26-22 08:45AM  
Apr-21-22 09:00AM  
Apr-20-22 04:01PM  
Apr-18-22 09:15AM  
Apr-12-22 08:55AM  
08:30AM  
Apr-11-22 09:00AM  
Mar-31-22 04:01PM  
Mar-24-22 06:25PM  
Mar-23-22 09:01AM  
Mar-01-22 07:36AM  
Feb-24-22 06:00PM  
04:01PM  
Feb-23-22 04:01PM  
Feb-17-22 03:02PM  
Feb-15-22 08:08AM  
Feb-10-22 04:01PM  
Feb-01-22 04:01PM  
Jan-21-22 11:37AM  
Jan-06-22 04:01PM  
Dec-28-21 04:01PM  
Dec-20-21 10:38AM  
Dec-18-21 09:15AM  
Dec-16-21 08:45AM  
Dec-07-21 04:35PM  
Nov-18-21 04:26PM  
Nov-12-21 09:03AM  
Nov-11-21 04:05PM  
Nov-04-21 09:35AM  
07:00AM  
Nov-02-21 07:01PM  
Oct-28-21 03:05PM  
Oct-26-21 05:45PM  
04:25PM  
Oct-21-21 09:00AM  
Oct-19-21 10:51AM  
Oct-18-21 12:26PM  
Oct-13-21 09:03AM  
Oct-12-21 09:10AM  
Sep-20-21 06:21AM  
Sep-18-21 10:50PM  
Sep-09-21 07:52AM  
Aug-26-21 04:01PM  
Aug-25-21 04:01PM  
Aug-17-21 11:42AM  
Aug-04-21 05:45PM  
04:01PM  
Aug-03-21 04:01PM  
Aug-02-21 04:05PM  
Jul-28-21 03:03PM  
Jul-21-21 04:01PM  
Jun-22-21 09:01AM  
Jun-11-21 07:00AM  
Jun-02-21 04:03PM  
May-18-21 04:01PM  
May-17-21 08:01AM  
May-05-21 06:05PM  
04:01PM  
03:15PM  
Apr-29-21 04:01PM  
Apr-28-21 12:34PM  
Apr-21-21 04:01PM  
Apr-12-21 07:24AM  
Apr-08-21 04:07PM  
Apr-01-21 08:22AM  
Mar-29-21 04:03PM  
Mar-08-21 05:00PM  
Feb-25-21 04:01PM  
02:45PM  
Feb-22-21 08:48PM  
Feb-17-21 09:01AM  
Feb-16-21 04:01PM  
Feb-09-21 05:02AM  
Feb-08-21 05:13PM  
Feb-04-21 04:01PM  
Jan-27-21 03:54PM  
Jan-26-21 10:09PM  
04:31PM  
Jan-23-21 06:40AM  
Jan-11-21 04:01PM  
Dec-28-20 04:01PM  
Dec-17-20 09:09AM  
09:07AM  
Dec-11-20 06:49PM  
Dec-09-20 04:07PM  
Nov-18-20 08:00AM  
Nov-16-20 09:00AM  
Nov-09-20 04:12PM  
Nov-06-20 09:31AM  
Nov-05-20 05:15PM  
04:01PM  
03:45PM  
Oct-29-20 12:35PM  
Oct-27-20 04:01PM  
Oct-22-20 04:01PM  
Personalis, Inc. operates as a cancer genomics company worldwide. The company provides sequencing and data analysis services to support the development of cancer therapies and large-scale genetic research programs. It offers NeXT Platform, which provides data analysis for tumor and its immune microenvironment, from a single limited tissue or plasma sample; ImmunoID Next for tumor profiling from tissue; NeXT Liquid Biopsy for tumor profiling from plasma; NeXT Personal, a liquid biopsy offering for personalized tumor tracking for patients; NeXT Dx Test, a genomic cancer profiling test enabling composite biomarkers for cancer treatment; and NeXT SHERPA and NeXT NEOPS for neoantigen prediction capabilities. The company also provides ACE platform for clinical and therapeutic applications such as neoantigen prediction, biomarker identification, and novel drug target selection. It serves biopharmaceutical customers, universities, non-profits, and government entities. The company has partnership with Mayo Clinic; MapKure, LLC; SpringWorks Therapeutics, Inc.; and Moores Cancer Center. Personalis, Inc. was incorporated in 2011 and is headquartered in Menlo Park, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Chen RichardChief Medical OfficerJun 17Sale3.291,5655,149146,488Jun 21 04:52 PM
Tachibana AaronChief Financial OfficerJun 17Sale3.293,44011,318231,943Jun 21 04:48 PM
Moore Stephen MichaelGeneral CounselJun 15Sale3.241,8325,93673,885Jun 17 05:11 PM
Chen RichardChief Medical OfficerJun 15Sale3.246,81822,090148,053Jun 17 05:08 PM
Tachibana AaronChief Financial OfficerJun 15Sale3.246,81822,090235,383Jun 17 05:02 PM
Tachibana AaronChief Financial OfficerJun 02Sale3.594,18715,031242,201Jun 06 05:36 PM
Chen RichardChief Medical OfficerJun 02Sale3.594211,511154,871Jun 06 05:30 PM
West John StephenPresident and CEOMay 16Sale4.862,40811,703382,444May 18 06:16 PM
Tachibana AaronChief Financial OfficerMay 16Sale4.861,2866,250246,388May 18 06:17 PM
Moore Stephen MichaelGeneral CounselMay 16Sale4.866643,22775,717May 18 06:15 PM
Chen RichardChief Medical OfficerMay 16Sale4.861,2866,250155,830May 18 06:14 PM
Moore Stephen MichaelGeneral CounselMay 02Sale5.535,73331,70376,381May 04 05:38 PM
West John StephenPresident and CEOApr 20Option Exercise1.8445,06182,912384,852Apr 22 05:25 PM
West John StephenPresident and CEOApr 13Option Exercise1.8464,430118,551404,221Apr 15 06:24 PM
Lightspeed Venture Partners SeAffiliate of 10% OwnerMar 03Buy9.83261,0112,565,7382,084,240Mar 04 08:27 PM
Lightspeed Venture Partners SeAffiliate of 10% OwnerMar 03Buy10.384,75049,3054,750Mar 04 08:27 PM
Lightspeed Venture Partners SeAffiliate of 10% OwnerMar 02Buy9.9648,989487,9301,823,229Mar 04 08:27 PM
Chen RichardChief Medical OfficerMar 02Sale10.184714,795157,334Mar 04 06:09 PM
Tachibana AaronChief Financial OfficerMar 02Sale10.184,51145,922251,441Mar 04 06:08 PM
Chen RichardChief Medical OfficerJan 28Sale9.937057,001157,805Feb 01 06:05 PM
Tachibana AaronChief Financial OfficerJan 28Sale9.937057,001255,952Feb 01 06:04 PM
West John StephenPresident and CEOJan 19Sale11.0164,503710,178285,457Jan 19 07:22 PM
West John StephenPresident and CEOJan 18Sale11.7335,484416,227349,960Jan 19 07:22 PM
Chen RichardChief Medical OfficerDec 17Sale12.801,56320,006158,510Dec 20 07:10 PM
West John StephenPresident and CEODec 17Sale12.802,73234,970385,444Dec 20 07:00 PM
Tachibana AaronChief Financial OfficerDec 17Sale12.803,43743,994256,657Dec 20 07:59 PM
West John StephenPresident and CEODec 16Sale13.4297,2681,305,337388,176Dec 17 09:17 PM
Chen RichardChief Medical OfficerDec 02Sale12.924195,41380,073Dec 06 06:06 PM
Tachibana AaronChief Financial OfficerDec 02Sale12.924,18454,057180,094Dec 06 06:05 PM
West John StephenPresident and CEONov 30Sale13.65100,0001,365,000485,444Dec 02 05:49 PM
West John StephenPresident and CEONov 17Sale17.042,34840,010585,444Nov 19 06:15 PM
Tachibana AaronChief Financial OfficerNov 17Sale17.041,25321,351184,278Nov 19 06:14 PM
Chen RichardChief Medical OfficerNov 17Sale17.041,25321,35179,781Nov 19 06:12 PM
West John StephenPresident and CEOOct 12Sale19.33100,0001,933,000587,792Oct 14 06:24 PM
Tachibana AaronChief Financial OfficerSep 17Sale21.253,15266,980185,531Sep 21 06:36 PM
Chen RichardChief Scientific OfficerSep 17Sale21.251,08823,12081,034Sep 21 06:35 PM
Tachibana AaronChief Financial OfficerSep 02Sale21.923,82083,734188,683Sep 07 05:51 PM
Chen RichardChief Scientific OfficerSep 02Sale21.922916,37982,122Sep 07 05:50 PM
Chen RichardChief Scientific OfficerAug 06Option Exercise0.0015,5640102,413Aug 10 05:19 PM
Chen RichardChief Scientific OfficerAug 06Sale21.224,43694,13282,413Aug 10 05:19 PM
West John StephenPresident and CEOJul 08Sale22.54110,0002,479,400635,520Jul 12 05:07 PM